Session Chair Profile

Ph.D., Co-founder and CEO, ArcherDX, Inc.

In 2013 Dr. Myers co-founded ArcherDx Inc. with Dr. A. John Iafrate and Dr. Long P. Le to develop NGS-based assays for clinical oncology, and joined Enzymatics as Chief Scientific Officer when ArcherDx was acquired by Enzymatics Inc later that year. In 2015, Dr. Myers reassumed the role of CEO at ArcherDX after the acquisition of specific assets of Enzymatics by Qiagen. Shortly after the semiconductor sequencing company Ion Torrent was formed Dr. Myers joined and worked with the team to develop the novel sequencing chemistry and system, eventually leading a cross-functional product development team to further develop the Ion Torrent technology and sequencing applications. Dr. Myers received his PhD in Molecular Pharmacology from Stanford University School of Medicine in 2005, followed by a post-doctoral fellowship where he developed novel microarray-based methods and software to investigate genome-wide regulation of post- transcriptional gene expression.

Session Abstract

Session Synopsis: NGS-based liquid biopsy assays have great promise for multiple clinical applications, but challenges associated with detection sensitivity, bioinformatic analysis and validation must be overcome in order to drive routine clinical adoption. Join leaders in the field as we discuss the progress, potential and remaining obstacles of using NGS for this application.

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).